Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Bladder Cancer

An Introduction to Bladder Cancer

Supported by:
EU BLADDER CANCER PARTNER
World Partner
touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more supportive healthcare culture.

Mark CompleteCompleted
BookmarkBookmarked

At #ASCO25, Professor Dickon Hayne presented results from the ANZUP 1301 trial showing that adding mitomycin C to BCG may offer a well-tolerated, effective option for high-risk NMIBC. The combination reduced BCG use by 40% – a significant finding amid global shortages – with encouraging efficacy and safety signals.

Mark CompleteCompleted
BookmarkBookmarked

This year, we are celebrating our inaugural touchONCOLOGY Future Leaders to recognize the outstanding talent that has entered our field in recent years. These individuals are set to innovate and transform oncology and haematology in the years to come.

Mark CompleteCompleted
BookmarkBookmarked

This May, the World Bladder Cancer Patient Coalition (WBCPC) is launching Bladder Cancer Awareness Month 2025 under the theme “Feeling Unsure? Get Checked”. The campaign highlights the importance of recognising blood in urine as a symptom of bladder cancer and acting quickly to seek medical advice.

36 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT OPINIONS
Dr Laura Mertens; Prof. Thomas Powles; Ms Lindsay Diamond

An oncologist, urologist and oncology nurse consider the use of perioperative immunotherapy in MIBC.

Developed by Touch
Coverage from: ESMO 2024

The NIAGARA trial evaluated the combination of durvalumab (D) with neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) and adjuvant durvalumab in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). A total of 1063 patients were randomized to either receive durvalumab + NAC + ...

Developed by Touch
Coverage from: ASCO 2024

Significant advancements in bladder cancer research emerged from ASCO 2024. To understand these, as well as the other key trials and highlights from the meeting, we spoke with the Clinical Director of the Genitourinary Cancer Program at the University of Washington and Fred Hutchinson Cancer Center, Prof. Petros Grivas. In this interview, Prof. Grivas delves into the findings from the EV-302 (NCT04223856), EV-101 (NCT02091999), EV-201 (NCT03219333), EV-301 (NCT03474107), CheckMate 901 (NCT03036098) and other trials, offering his valuable insights into the impact the results could have on clinical practice, and particularly in the treatment of bladder

32 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked

Prof. Powles considers the latest developments in the treatment of advanced urothelial carcinoma.

16 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked

A GU oncologist shares insights into HER2 overexpression, testing and targeting in urothelial carcinoma.

39 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION
Dr Axel Merseburger, Dr André Fay, Ms Maria Laupuente

An oncologist, urologist and nurse discuss adverse event identification and management with immunotherapies and targeted therapies.

Mark CompleteCompleted
BookmarkBookmarked

Bladder cancer is one of the most common malignancies in the USA, with an estimated 81,180 new cases and 17,100 deaths in 2022.1 Advanced urothelial carcinoma (aUC) includes both locally advanced, unresectable and metastatic urothelial cancer. About 5% of all bladder cancer cases present ...

Mark CompleteCompleted
BookmarkBookmarked
Kana T Lucero, James Yoo, Chethan Ramamurthy

Bladder cancer (BC) is the sixth most common cancer in the world, accounting for 81,180 estimated new cases and 17,100 deaths in 2022.1 BC is most frequently diagnosed among people aged 65–74 years.1 For patients with disease limited to the bladder, the depth of ...

59 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchCONGRESS
Prof. Axel Merseburger, Dr Bradley McGregor, Prof. Andrea Necchi

Watch this two-part activity exploring recent advances in immunotherapies and targeted treatments for patients with bladder cancer. Filmed following the ESMO 2022 Congress. Part 1: Watch urological cancer expert Prof. Axel Merseburger review key data from the ESMO Congress 2022 Watch Now Part 2: Choose from leading experts who discuss what these data may mean for global and regional practice Select An Interview

Developed by Touch
Coverage from: ESMO Highlights

Patients with locally advanced bladder cancer have a poor prognosis despite surgical therapy. Prof. Sebastian Schmid (Technical University of Munich, Munich, Germany) joins touchONCOLOGY to discuss the unmet needs in the treatment of locally advanced bladder cancer, and also discusses ...

Developed by Touch
Coverage from: ASCO Highlights

Cabozantinib is a targeted therapy used to treat many forms of cancers. Prof. Robert Jones (University of Glasgow, Scotland, United Kingdom) discusses the rationale, design, and findings of the randomised phase 2 ATLANTIS trial, of maintenance cabozantinib following chemotherapy for metastatic ...

Developed by Touch
Coverage from: AACR Highlights

touchONCOLOGY were delighted to talk with Dr. Neal Shore (GenesisCare; Carolina Urologic Research Center, Myrtle Beach, SC, USA) to discuss the phase 3 study of pembrolizumab plus chemoradiotherapy in the treatment of muscle-invasive bladder cancer. The abstract ‘KEYNOTE-992: A randomized phase 3 ...

Coverage from: ASCO Highlights

touchONCOLOGY joins Professor Stephen B Williams (Chief, Division of Urology, Professor of Urology and Radiology, Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA) at ASCO 2021 to discuss the efficacy of TAR-200 in combination with cetrelimab in ...

Coverage from: ASCO Highlights

touchONCOLOGY joins Dr Joaquim Bellmunt (Director, Bladder Cancer Program, Beth Israel Deaconess Medical Center; Associate Professor of Medicine, Harvard Medical School, Boston, MA, USA) at ASCO 2021 to discuss the 5-year follow-up from the phase 3 KEYNOTE-045 trial. The abstract ‘A Study ...

Load More...
Close Popup